Skip to content

Prescribing Anti Depressant Appropriately.

Prescribing Anti Depressant Appropriately.

Status
Active, not recruiting
Phases
Unknown
Study type
Interventional
Source
NL-OMON
Registry ID
NL-OMON25490
Enrollment
360
Registered
2009-09-28
Start date
2009-01-12
Completion date
Unknown
Last updated
2024-02-28

For informational purposes only — not medical advice. Sourced from public registries and may not reflect the latest updates. Terms

Conditions

inappropriate long term anitedepressant use cost effectiveness collaborative care depression doelmatigheid antidepressiva kosten effectiviteit depressie

Interventions

Trial 1: The active intervention in trial 1 (absence of indication for antidepressant drugs) implies the discontinuation of antidepressant use, following the recommendations in the Dutch multidiscipl

Sponsors

None
Lead Sponsor

Eligibility

Inclusion criteria

Inclusion criteria: Long-term use of antidepressants is defined as receiving antidepressant prescriptions for at least nine months with a prescribed amount sufficient for at least 180 days of consumption in accordance with the recommended dosage.

Exclusion criteria

Exclusion criteria: 1. Current treatment in a psychiatric setting; 2. History of psychosis, bipolar disorder, or obsessive compulsive disorder; 3. Addiction; 4. Recurrent depression with 3 or more episodes; 5. Recurrent disorders with at least two relapses after antidepressant-discontinuation.

Design outcomes

Primary

MeasureTime frame
Trial 1: Proportion of participants who successfully discontinue their long-term antidepressants drug use, defined as having no antidepressant drug use within the last 6 months of the follow-up and the absence of a mood- or anxiety disorder during one-year follow-up. Trial 2: Proportion of participants in which the mood or anxiety found at baseline, has remitted at one-year follow-up.

Secondary

MeasureTime frame
Assessment of dimensional measures of psychopathology with both general and disease-specific questionnaires (see listing of questionnaires in the description of the study procedure). Also, to assess the prevalence of the discontinuation syndrome we will use the Discontinuation-Emergent Signs and Symptoms (DESS) Scale [35]. The EuroQol will be included to enable the economic analyses. Costs will be measured by the Trimbos/iMTA questionnaire for Costs associated with Psychiatric Illness (TiC-P).

Contacts

Public ContactE.M.H. Muskens

Postbus 9101

E.Muskens@elg.umcn.nl+31 (0)24 3655327

Outcome results

None listed

Source: NL-OMON (via WHO ICTRP)